ClinicalTrials.gg
RecruitingNCT04543799SIESTAUpdated Nov 18, 2025

Evaluation of Sleep Quality in Prostate Cancer Patients Undergoing Treatment With Hormonal Therapeutic Approaches and in Patients With Full-resected Early Breast Cancer

An observational study in Prostate Cancer and Breast Cancer, sponsored by Oncology Institute of Southern Switzerland. Recruiting at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-18.

Sponsored by Oncology Institute of Southern Switzerland · Observational

How we know

From the registry’s dates

  • Started Sep 2020; still recruiting 6 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
60
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 136 studies in Prostatic Neoplasms with a site in Switzerland — 40 open to participants now, 58 under way, 20 of them phase 3. Prostatic Neoplasms · Switzerland.

Planned enrollment
20th of 28
60 · median 219
Started
2020
with 4 others
Observational
28 of 136
9 open now
Primary completion
2026-12
later than 17 of 57 live
Registered
81st of 136
by date
Lead sponsor
5 of 136
Oncology Institute of Southern Switzerland

Among the 136 studies in Prostatic Neoplasms with a site in Switzerland, this one is the 20th largest by planned enrollment of the 28 observational ones that give a count, is one of 5 that started in 2020, is one of 28 observational ones, reaches primary completion later than 17 of the 57 other live ones, and was the 81st registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

40 of the 136 studies in Prostatic Neoplasms with a site in Switzerland are open now. Recruiting first, the newest first:

35 more — sign in →

All 40 open studies →

A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 136 studies in Prostatic Neoplasms with a site in Switzerland, or all of them as a file.
02

Study summary

This study will use polysomnography, alongside other methodologies such as questionnaires, actigraphic measurements and salivary melatonin samples used in previous studies to investigate sleep quality in patients with i) localized, locally advanced or metastatic hormone sensitive prostate cancer or ii) with full-resected early (stage I-III) epithelial breast cancer. The measurements will be taken before androgen deprivation therapy (ADT - for prostate cancer patients) or endocrine therapy (for breast cancer patients) is initiated, at 6 months and some measures again at 12 months.The groups, defined by cancer type and whether or not treatment includes ADT / endocrine therapy, will be compared to see if there are differences in the prevalence of the lowered sleep quality in the groups.

Read the detailed description

The main outcomes of this pilot study can be summarised as:

  • Using a previously unused methodology to assess whether ADT / endocrine therapy may negatively affect patterns of sleep quality
  • Identifying sleep micro/macrostructure changes in prostate cancer patients receiving ADT / endocrine therapy
  • Comparing the novel methodology with results obtained previously through standard methods
  • Providing statistical underpinnings, such as sample size calculations, for a full interventional trial
  • Highlighting the most appropriate non-pharmaceutical interventions to be tested in the full interventional trial
03

Conditions studied

  • Prostate Cancer
  • Breast Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

i) Patients with localized, locally advanced or metastatic hormone-sensitive prostate cancer receiving standard of care treatment (including radiotherapy with or without androgen-deprivation treatment (ADT) or ADT alone +/- androgen receptor targeted agent) dependent on disease stage ii) Patients with full-resected early (stage I-III) epithelial BC, ductal carcinoma in situ or lobular carcinoma in situ, without evidence of residual disease

Eligibility criteria

Inclusion Criteria for prostate cancer patients:

  • Written infor med consent according to International Conference on Harmonisation (ICH)/Good Clinical Practice (GCP) regulations before registration and prior to any trial specific procedures
  • proven adenocarcinoma of the prostate
  • performance status 0-2
  • Adult male patient > 18 years of age, no upper age limit
  • Localized prostate cancer, locally advanced hormone-sensitive prostate cancer (HSPC) or hormone-sensitive prostate cancer (mHSPC)
  • ADT recipients are required to be scheduled to start ADT as standard of care (SOC) for metastatic or locally advanced prostate cancer
  • Scheduled to receive ADT treatment as SOC for > 6 months in combination with radiotherapy or oral AR-targeted systemic treatment as prescribed by the treating physician or radiotherapy alone

Exclusion Criteria for prostate cancer patients:

  • Histology with predominant small cell prostate cancer
  • Any previous treatment with ADT or oral AR-targeted agent (exception for short course anti-androgens - disease flare)
  • Have not received systemic treatment for any other cancer within the last 12 months
  • Active secondary that requires systemic therapy
  • Any clear present against treatment with ADT
  • Presence of sleep apnea syndrome, Apnea Hypopnea Index (AHI) >15 at baseline
  • (BMI) > 35 at baseline
  • Severe respiratory disorders (asthma, ) at baseline
  • Severe cardiovascular disease or severe cardiovascular event \< 6 months
  • History of stroke or other neurologic chronic illnesses \< 6 months
  • Have demonstrated impaired mental status
  • History of brain tumours, presence of or previous cranial irradiation
  • Night shift workers
  • Excessive lifestyle: massive coffee intake at night, regular excessive cigarette and alcohol consumption in the evening
  • Unhealthy sleep hygiene
  • Nocturia (the urgent need to urinate more than 2 times during the main sleep period at night) at baseline
  • Present diagnosis of depression or psychiatric illness pharmacologically treated
  • Diagnosis of insomnia and chronic intake of hypnotic medication at baseline
  • Chronic intake of medications that are known to induce sleep disturbance (antihistamines of first generation, cortisone intake > 25 mg/day)
  • Any diagnosed condition that causes known sleep disturbance

Inclusion criteria for breast cancer patients

  • Written according to International Conference on Harmonisation (ICH)/Good Clinical Practice (GCP) regulations before registration and prior to any trial specific procedures
  • Women with full-resected early (stage I-III) epithelial BC, ductal carcinoma in situ or lobular carcinoma in situ, without evidence of residual disease
  • Eastern Cooperative Oncology Group performance status 0-2
  • Adult female patient ≥ 18 years of age, no upper age limit
  • Proven status (defined by absence of menstruation for at least 6 months and/or level of estradiol \<40 pg/ml, or bilateral oophorectomy or ovarian irradiation for suppression of ovarian function)

Exclusion criteria for breast cancer patients

  • Non-epithelial BC or BC with mixed epithelial and non-epithelial histology
  • Previous chemotherapy at any time, in treatment with ET at not standard dosage
  • Have received systemic treatment for any other cancer within the last 12 months
  • Active secondary malignancy that requires systemic therapy
  • Presence of sleep apnea syndrome, Apnea Hypopnea Index (AHI) >15 at baseline
  • Body mass index (BMI) > 35 at baseline
  • Severe respiratory disorders (asthma, Chronic obstructive pulmonary disease) at baseline
  • Severe cardiovascular disease or severe cardiovascular event \< 6 months
  • History of stroke or other neurologic chronic illnesses \< 6 months
  • Have demonstrated impaired mental status
  • History of brain tumours, presence of brain metastases or previous cranial irradiation
  • Night shift workers
  • Excessive lifestyle: massive coffee intake at night, regular excessive cigarette and alcohol consumption in the evening
  • Unhealthy sleep hygiene
  • Nocturia (the urgent need to urinate more than 2 times during the main sleep period at night) at baseline
  • Present diagnosis of depression or psychiatric illness pharmacologically treated
  • Diagnosis of insomnia and chronic intake of hypnotic medication at baseline
  • Chronic intake of medications that are known to induce sleep disturbance (antihistamines of first generation, cortisone intake > 25 mg/day) or any diagnosed condition that causes known sleep disturbance
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
60 participants (estimated)
Patient registry
No

Groups and cohorts

  • A1

    Group A1 consists of patients with prostate cancer receiving ADT as part of their standard care for either locally advanced or metastatic disease. Group A1 consists of a combination of two groups; B1, metastatic patients receiving ADT both with and without an oral AR targeted agent, and not receiving radiotherapy and B2, locally advanced patients receiving ADT alongside radiotherapy

    Device: polysomnography, actigraphy, questionnaires

  • A2

    patients with localised prostate cancer receiving radiotherapy only

    Device: polysomnography, actigraphy, questionnaires

  • YET

    Breast cancer survivors receiving endocrine therapy

    Device: polysomnography, actigraphy, questionnaires

  • NET

    Breast cancer survivors not receiving endocrine therapy

    Device: polysomnography, actigraphy, questionnaires

Interventions

  • Devicepolysomnography, actigraphy, questionnaires

    sleep quality recording

06

What researchers measure

Primary outcomes

  1. difference in sleep quality

    The two groups considered will be group A1, and group A2. This will demonstrate whether there is a difference in sleep quality between these two groups of patients. The difference between time points will establish correlation between treatment initiation and symptom onset, the between group analysis will test whether the link seems to be radiotherapy alone or whether ADT further decreases sleep quality

    Time frame: 1 year

07

Study locations

1 of 1 sites recruiting
  • IOSI
    Bellinzona, 6500, Switzerland
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2020 (actual). Primary completion is estimated for Dec 2026, 75 months after the start.

Of 542 non-industry observational studies under Prostatic Neoplasms, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 162. This study's planned 75 months is above that.

Counting every sponsor, half of 651 studies reached it within 60 months; a quarter within 28 and three quarters within 141.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 2, 2020
First posted
Sep 10, 2020
StartActual
Sep 24, 2020
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Nov 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04543799
Lead sponsor
Oncology Institute of Southern Switzerland
Responsible party
Sponsor
First posted
Sep 10, 2020
Start date
Sep 24, 2020
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Nov 18, 2025

Study contacts

Ursula Vogl, MD
Contact
ursula.vogl@eoc.ch
+419181113308463

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion